alexa Efficacy of Combination Therapy with rhTNFR:Fc and Methotrexate in the Patients with Disease-modifying Antirheumatic Drug -resistant Rheumatoid Arthritis

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Efficacy of Combination Therapy with rhTNFR:Fc and Methotrexate in the Patients with Disease-modifying Antirheumatic Drug -resistant Rheumatoid Arthritis

Objective: To observe the efficacy of combining recombinant human tumour necrosis factor-Fc [rhTNFR:Fc ,etanercept] and methotrexate (MTX) in patients with disease-modifying antirheumatic drug (DMARD)-resistant rheumatoid arthritis . Methods: Collected 64 active RA patients with DMARD-resistant, according to patients’ gender, age, duration and extent of disease activity, divided the 64 patients randomly into comparable two groups. The experimental group within thirty-two patients, were treated with twice-weekly subcutaneous etanercept (25 mg) and meanwhile weekly oral MTX (15 mg);the control group within thirty-two patients, were treated with daily oral prednisone (5-10 mg) and meanwhile weekly oral MTX (15 mg).

 

Citation: Wen-yi F, Ning Z, Lili Y (2012) Efficacy of Combination Therapy with rhTNFR:Fc and Methotrexate in the Patients with Disease-modifying Antirheumatic Drug -resistant Rheumatoid Arthritis. J Arthritis 1:104. 

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger